IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

SK Chemicals and IVI on collaborative vaccine development

Author
Hong
Date
2012-11-12 00:00
Views
7325
 

SK Chemicals and IVI sign MOU on collaborative vaccine development

 

  • Supply 10 million typhoid vaccine doses to developing countries through UNICEF every year
  • To implement the company’s mission; ‘HEALTHCARE, EARTHCARE’ and to present a symbolic approach for the future of vaccine business

 

Seoul, October 9, 2012— SK Chemicals (CEO, Chang-Geun Kim) announced today that it has signed a Memorandum of Understanding (MOU) with International Vaccine Institute (IVI, Director-General Christian Loucq) to collaborate on Typhoid vaccine development and supply.

 

The collaboration will focus on the establishment of a global vaccine system to protect children from the risk of Typhoid fever in developing countries.

 

Under the terms of this MOU, SK Chemicals and IVI will exchange their technology for the development of a Typhoid vaccine and will collaborate on future clinical studies and application for the prequalification from the World Health Organization (WHO). SK Chemicals will manufacture and supply about 10 million doses of the Typhoid vaccine to developing countries through the United Nations Children’s Fund (UNICEF).          

 

 
Dr. Christian Loucq, IVI Director-General, and Chang-Geun Kim, CEO of SK Chemicals, at SK Chemicals headquarters in Seoul after the MOU signing ceremony.

 

"We are very excited about this collaboration with SK Chemicals to protect children in developing countries from Typhoid," IVI Director-General Dr. Christian Loucq said. "IVI appreciates SK Chemicals’ commitment to, and efforts towards improving global health. IVI and SK Chemicals will work closely together to reduce the burden of Typhoid fever in developing countries."

 

Chang-Geun Kim, CEO of SK Chemicals said "SK Chemicals has started a vaccine business to implement our company's mission: 'Contribution to improvement of human health.' I strongly believe that the collaboration with IVI on global vaccine project is an important opportunity not only to practice our mission but also to present a symbolic approach to the future of vaccine business."

 

Typhoid fever is a bacterial disease, transmitted through ingestion of food or water contaminated with the feces or urine of infected people. Although Typhoid fever is practically under control in most developed countries, it is still common in developing countries with a poor water and sanitation system. According to the US Centers for Disease Control and Prevention (CDC), about 21 million people are suffering from Typhoid fever and more than 200,000 deaths occur world-wide every year.

 

IVI, the first international organization to be hosted by the Korean government, was officially established in 1997 as an independent international nonprofit organization with an aim to effectively control infectious disease affecting the world's poorest children through the accelerated and sustainable creation of new vaccines and their introduction into countries worldwide.

 

SK Chemicals has been developing Korea’s first cell culture-based influenza vaccine in order to secure a vaccine supply in a pandemic situation. By the second half of 2014, SK Chemicals will complete construction of a state-of-the-art manufacturing facility with a capacity of 140 million vaccine doses annually.

 

In addition to the vaccine development program, SK Chemicals has been supportive to the IVI’s philanthropic activities. In June 2012, SK Chemicals participated in the 'Blue & Green Ribbon Charity Gala,' co-hosted by IVI to call attention to the need for improving the health of North Korean children and committed to support of North Korean Children.            

 

 

DONATE